Medicare's stance on weight-loss drugs changed meaningfully in 2026 with a first-ever obesity program. Here is exactly what is and isn't covered.
Does Medicare cover weight-loss drugs in 2026?
By law, Medicare Part D cannot cover any drug used only for weight loss, a rule that still stands in 2026. The major change is the CMS GLP-1 Bridge, a temporary demonstration effective July 1, 2026 that lets eligible Part D members access Zepbound (KwikPen) for obesity at a $50 copay per 30-day supply through December 31, 2027. Separately, GLP-1 drugs can be covered under standard Part D for approved medical uses, such as Ozempic and Mounjaro for diabetes or Wegovy for cardiovascular risk. Call 1-800-MEDIGAP to see which path fits you.
Who qualifies for weight-loss drug coverage under the GLP-1 Bridge?
To use the 2026 GLP-1 Bridge, you must be enrolled in a participating Medicare Part D plan and generally have a BMI of 35 or higher, or a BMI of 30 to 34.99 with a qualifying condition such as diastolic heart failure or uncontrolled high blood pressure. The program covers Zepbound KwikPen for a flat $50 copay per 30-day supply but excludes single-dose vials. Importantly, that copay does not count toward your deductible or the 2026 $2,100 out-of-pocket cap, because it runs outside the standard Part D benefit.
How do approved medical uses change coverage?
Even outside the Bridge, GLP-1 drugs can be covered when prescribed for an approved condition Medicare already pays for. Ozempic and Mounjaro may be covered for type 2 diabetes; Wegovy may be covered to reduce cardiovascular death, heart attack, or stroke risk in qualifying adults; and Zepbound may be covered for obstructive sleep apnea. Coverage always depends on the diagnosis and your plan's formulary, and plans often require prior authorization. A free review at 1-800-MEDIGAP matches your prescriptions and diagnoses to plans that cover them.